RecruitingNCT01967511

Defining the Basis of Fibromuscular Dysplasia (FMD)

Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

600 participants

Start Date

Oct 1, 2013

Study Type

OBSERVATIONAL

Conditions

Fibromuscular Dysplasia Cervical Artery Dissection Spontaneous Coronary Artery Dissection

Summary

The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cervical artery dissection, fibromuscular dysplasia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.